These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33929085)

  • 21. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.
    Piening S; Haaijer-Ruskamp FM; de Graeff PA; Straus SM; Mol PG
    Drug Saf; 2012 Nov; 35(11):1061-72. PubMed ID: 23061782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors.
    Hoeve CE; de Vries E; Mol PGM; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2021 Jan; 44(1):73-82. PubMed ID: 33355904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study.
    Roldan Munoz S; Postmus D; de Vries ST; Gross-Martirosyan L; Bahri P; Hillege H; Mol PGM
    Drug Saf; 2023 Mar; 46(3):243-255. PubMed ID: 36790560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Communication and the Pharmaceutical Industry: what is the reality?
    Edwards B; Chakraborty S
    Drug Saf; 2012 Nov; 35(11):1027-40. PubMed ID: 23061779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation of adverse drug reactions in Saudi Arabia: A retrospective observational study.
    Alenzi KA; Alanazi NS; Almalki M; Alomrani H; Alatawi FO
    Saudi Pharm J; 2022 Jun; 30(6):735-741. PubMed ID: 35812140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experiences and Perspectives of Marketing Authorisation Holders towards Medication Safety Monitoring during Pregnancy: A Pan-European Qualitative Analysis.
    Sillis L; Foulon V; Verbakel JY; Ceulemans M
    Int J Environ Res Public Health; 2022 Apr; 19(7):. PubMed ID: 35409928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why do general practitioners disregard direct to healthcare professional communication? A user-oriented evaluation to improve drug safety communication.
    Møllebaek M; Kaae S
    Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):463-471. PubMed ID: 33043558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges of drug risk communications in the Philippines.
    Hartigan-Go K
    Drug Saf; 2012 Nov; 35(11):995-1004. PubMed ID: 23061777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries.
    Heintjes EM; Bezemer ID; Prieto-Alhambra D; Smits E; Booth HP; Dedman D; He Y; Hoti F; Vehkala M; de Vogel S; Robinson NJ; Appenteng K; Penning-van Beest FJA
    Clin Epidemiol; 2020; 12():423-433. PubMed ID: 32431551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.
    Zeitoun JD; Lefèvre JH; Downing N; Bergeron H; Ross JS
    PLoS One; 2014; 9(10):e109100. PubMed ID: 25333986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The Pharmaceuticals and Medical Devices Agency's Approach to Facilitate Risk Communication and Its Challenges].
    Kondo E; Torii M; Oba I; Okamoto M
    Yakugaku Zasshi; 2018; 138(3):307-314. PubMed ID: 29503421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands.
    Oosterhuis I; van Hunsel FP; van Puijenbroek EP
    Drug Saf; 2012 Mar; 35(3):221-32. PubMed ID: 22201474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knowledge, attitude, practice and barriers towards pharmacovigilance and adverse drug reactions reporting among healthcare professionals in Turkey: a systematic review.
    Khan Z; Karatas Y; Martins MAP; Jamshed S; Rahman H
    Curr Med Res Opin; 2022 Jan; 38(1):145-154. PubMed ID: 34694167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.